Background: Th ere is equivocal evidence of the eff ectiveness of adherence therapy in
Introduction
It has been estimated that non-adherence rates for prescribed antipsychotic medications are about 50% (Nose et al., 2003a) . Relapse rates have been shown to be fi ve times higher in people with schizophrenia who are non-adherent to medication compared with adherent people, resulting in a signifi cant social and economic burden (Robinson et al., 1999) . Zygmunt et al. (2002) reviewed randomised controlled trials of adherence interventions in schizophrenia. Th ey showed that only one-third of these studies reported signifi cant treatment eff ects, but that interventions based upon the principles of motivational interviewing were 'promising'. A subsequent meta-analysis concluded that psychiatric services could use eff ective clinical interventions for reducing patient non-adherence, but that the benefi t of these interventions would be more evident in the short-term than in the long term (Nose et al., 2003b) . A recent randomised controlled trial of in-patients compared adherence therapy with non-specifi c counselling over 1 year, and found no clear advantage (O'Donnell et al., 2003) .
Method
Th e main aim of this study was to compare the eff ectiveness of adherence therapy with a health education control intervention (which allows for therapist time and relationship), in improving health-related quality of life for people with schizophrenia receiving treatment from general adult mental health services in four European cities. Th e primary a priori hypothesis was that adherence therapy would result in improved quality of life for people with schizophrenia, compared with health education. Secondary a priori hypotheses were that, compared with health education, adherence therapy would improve medication adherence and symptoms.
Th e study design was a two-arm randomised controlled trial, with masking of assessors to the status of the participants. Th e interventions were delivered in routine general adult psychiatric settings, to maximise the generalisability of the results of this eff ectiveness trial (Tunis et al., 2003 
Study procedures
Individuals participated only if they gave written, informed consent. All study sites gained full approval for the study from the appropriate local research ethics committee (institutional review board). Once participants had given consent, they underwent baseline interviews and then received a unique identifi cation number. Th is was sent to an independent clinical trials unit, where allocation was carried out by permuted blocks of random size, stratifi ed by centre. Th e allocation was notifi ed to the therapist, who arranged directly with the participant for the allocated treatment to be given. Th e researcher who conducted the baseline interview and the follow-up assessment remained masked to allocation throughout the study, to minimise bias. Participants were not masked to whether they were receiving adherence therapy or health education, and consequently binnenwerk m kikkert.indd 40 binnenwerk m kikkert.indd 40 9- 1-2010 18:35:15 9-1-2010 18:35:15 this cannot be considered a double-blind trial. However, participants were informed that they would receive one of two interventions but were not told which was regarded by the investigators as the experimental intervention, and remained masked to the exact aims of the study.
Study interventions
Th e experimental intervention, adherence therapy, is a brief individual cognitivebehavioural approach (Gray et al., 2004; Kemp et al., 1996 Kemp et al., , 1998 . Th e adherence therapy manual (http://www.adherencetherapy. com) describes a collaborative, patient centred phased approach to promoting treatment adherence in people with schizophrenia. Th ere are six elements that form the core of the therapy: assessment; medication problemsolving; a medication timeline; exploring ambivalence; discussing beliefs and concerns about medication; and using medication in the future. Key therapy skills that therapists use include exchanging information, developing discrepancy between the patient's thoughts and behaviours about medication, and working with resistance to discussing psychiatric medication and treatment. Th e aim of the therapy process is to achieve a joint decision about medication between the individual and therapist. A central tenet of the therapy is that where patients and therapists make choices about treatment together, adherence to that regimen will be enhanced.
Previous trials of adherence interventions have used a non-specifi c counselling intervention or standard care as the control intervention (Zygmunt et al., 2002) . We off ered participants a control intervention that would be acceptable and was not expected to enhance medication adherence, but which did control for the time spent with the therapist (Roth & Fonagy, 1996) . We chose didactic health education rather than standard care alone as the control condition, to control for therapist time and other nonspecifi c aspects of the intervention. Th e eight individual sessions of the health education package included presentations on health education-related topics such as diet and healthy lifestyle. Th erapists presented information in a didactic way, and were trained not to use any adherence therapy skills or techniques. a. Both adherence therapy and health education interventions were described in detail in manuals.
b. Th e English language manuals were translated and back-translated into the appropriate languages (Dutch, German and Italian).
c. All therapists met for 7 days to receive intensive training, using videomodelling and role-play rehearsal of key skills.
d. Randomly selected therapy sessions (37) were audiotaped and independently rated using the Adherence Th erapy Checklist (ATC; Vallis et al., 1986 ).
e. Th roughout the 18 months of the intervention period, therapists attended monthly group telephone clinical supervision, focusing on case presentations, the resolution of clinical problems, and adherence to therapy manuals. Both adherence therapy and health education were off ered at each site in addition to treatment-as-usual, which consisted of regular contact with psychiatrists and case managers, pharmacological therapy and the availability of day care, social support and acute hospital admission as required (Becker et al., 2002) .
Outcome measures
Assessments took place at baseline and at 1 year after randomisation. Th e assessment scales included measures of sociodemographic characteristics, quality of life, adherence and psychopathology. Th e key results for the following scales are reported.
Medical Outcome Study (MOS) 36-Item
Short Form Health Survey (SF-36) Th e SF-36 is a self-report multidimensional survey measure of health-related quality of life and well-being (Ware & Sherbourn, 1992) . Th e scales of the SF-36 address eight health domains, and two summary measures are provided: a physical component summary score (PCS) and a mental component summary score (MCS). Th e MCS was selected as the main quality of life (QoL) outcome measure, as it has been shown to have good sensitivity to change, which is uncommon among QoL measures (Rood et al., 2000) . Further, in people with severe mental illness, the SF-36 has been found to have well-established psychometric properties (test-retest reliability and internal consistency) (Russo et al., 1998; Tunis et al., 1999) .
Schedule for the Assessment of Insight -Expanded Version (SAI-E)
From this semi-structured interview, we used the keyworker rating of adherence, referred to as the SAI-C, on a scale ranging from 1 (complete refusal) to 7 (active participation in treatment) (David, 1990) . 
Medication Adherence Questionnaire (MAQ)
Th e MAQ addresses how patients may fail to take their medication as prescribed, for example because of forgetfulness, carelessness, stopping the drug when they feel better, or stopping the drug because they believe it makes them feel worse. Th e scale has good levels of validity and reliability (Morisky et al., 1986) .
Brief Psychiatric Rating Scale -Expanded (BPRS-E)
Th e BPRS-E consists of 24 items measuring psychiatric symptoms (Lukoff et al., 1986; Ventura et al., 1993) . It measures four diff erent dimensions: positive symptoms, negative symptoms, depression and anxiety and manic excitement or disorganisation.
Sample size
A sample size of 300 participants was sought (150 in the treatment and 150 in the control group). Th is was suffi cient to detect an overall diff erence between intervention and control of six points in the SF-36 MCS scale, based upon previous studies using such a magnitude of clinical change (Ware & Kosinski, 2003a ) and equivalent to a medium standard eff ect size, with over 99% power. Th e calculation assumes that the analysis would adjust for baseline values, that the pre-post correlation would be 0.5, and a standard deviation of the MCS of about 12, as found in MOS patients (adults in various settings with depression in the USA) (Ware & Kosinski, 2003b) . With an estimated 25% attrition rate, this required the recruitment of 400 participants (100 per site on average) at baseline.
Statistical methods
Th e eff ect of the intervention on the outcomes was assessed by comparing the mean values for intervention and control at follow-up using analysis of covariance (Mickey et al., 2004) to control for baseline value and site. Th e analyses were completed on an intention-to-treat basis. Double-sided critical levels for signifi cance tests were used. Prorating dealt with missing items in the computation of sub-scales for each participant, so long as there were fewer than 20% missing items for that person; otherwise, the scale was set to missing. Th is rule was overridden where there were specifi c instructions for the scale up values were also imputed from baseline values, and any other relevant variables at follow-up, if available. As a further sensitivity analysis, the MAQ and SAI-C scales, which were short scales with non-normally distributed data, were analysed using ordered logistic regression. Microsoft Access databases and SPSS version 11 for Windows were used for initial data acquisition and checking, and Stata version 8.2 for the analyses.
Results

Socio-demographic characteristics
Th e randomisation produced no substantial diff erences between the control and treatment groups at baseline ( Table 1) . As is common in treated prevalence studies of schizophrenia, the mean age of the sample was in the early forties, the slight majority were male, and relatively few were married or cohabiting. Th ree-quarters of the participants were White, and almost half lived alone, usually in owned or rented accommodation; only about 15%
were in paid employment.
Clinical characteristics
At baseline there were no substantial clinical diff erences between the control and treatment groups (Table 1) . Participants in both groups had spent about 1 month in the year before baseline as in-patients, and had been treated with antipsychotic medication for about 12 years. Between sites there were some diff erences in the profi les of symptoms and disability, but the variations in patterns of service use were more marked and refl ected diff erent service confi gurations in each of the four areas studied (Table 2) (Chisholm & Knapp, 2002) . Figure 1 shows the fl ow of participants through the study in the CONSORT format.
Participant fl ow
Of the 1218 people screened, 917 were eligible to participate in the study. Of these, 366 (39.9%) refused to participate, 142 (15.5%) could not be randomised for other reasons, so a total of 409 (44.6%) were randomised. Th e three most common reasons for refusing to participate in the study were that potential participants did not have enough time,
were not interested in the study or did not want to participate in research. (74) 159 (78) 310 (76) Primary/secondary education only, n (%) 136 (67) 135 (67) 271 (67) Living alone, n (%) 84 (41) 81 (40) 165 (40) Living with partner, n (%) 31 (53) 28 (48) 
Study completion and attribution rates
Baseline and follow-up data for the core outcome measures were collected for 349 (85.3%) participants: 184 (90%) in the health education group and 165 (81%) in the adherence therapy group, a diff erence in follow-up rate that was statistically signifi cant (p=0.01). Table 3 shows that, overall, people who dropped out of the trial tended to have had more in-patient days (p=0.022), but in other respects were similar to those who completed the interviews, and the drop-outs were similar in the two arms. (73) 55 (57) 50 (54) 67 (56) White European, n (%) 44 (44) 97 (100) 49 (53) 120 (100) Antypsychiatric admission in past year, n (%) 40 (40) 72 (74) 24 (26) 23 (19) BPRS, Brief Psychiatric Rating Scale.
1. n=366 for years ofmedication; for other variables, n=406-409.
Independent evaluation of 20 audiotapes of health education and 17 of adherence therapy, using the ATC, revealed that the adherence therapy was delivered in a way that was highly consistent with the adherence therapy manual. Participants receiving health education did not receive any of elements of adherence therapy.
Outcomes of intervention
Quality of life
Th ere were no signifi cant diff erences in quality of life between the two intervention groups at baseline or at follow-up (Table 4) . Sensitivity analyses confi rmed this fi nding.
Medication adherence
Th ere was no signifi cant diff erence between adherence therapy and health education at follow-up. Th is indicates that interventions were essentially equivalent. Sensitivity analyses did not reveal any major diff erence in these fi ndings. We conducted an exploratory post-hoc analysis to examine the eff ect of adherence therapy in a subgroup of the less treatment adherent participants (defi ned as a score of 2 or lower on the MAQ). Although such an analysis was not planned a priori, it was considered informative to explore any possible eff ect of adherence therapy in a sample of non-adherent individuals. Just under a third of the sample (n=120, 30%) met this criterion. Th ere was no signifi cant diff erence in medication adherence between the groups at follow-up.
Referred by clinicians as meeting criteria n=1218 (60) 8 (62) 115 (60) 17 (59) Married/cohabiting, n (%) 20 (10) 2 (15) 24 (14) 1 (3) White European, n (%) 149 (78) 10 (77) 130 (74) 21 (72) No education beyond secondary level,
126 (66) 9 (69) 116 (67) 21 (72) Living alone, n (%) 79 (41) 2 (15) 70 (40) 14 (48) Psychiatric 
Discussion
Th is study showed that adherence therapy had no clear benefi t in terms of treatment adherence, psychopathology or quality of life when compared with health education, for people with generally chronic schizophrenia, in general adult mental health services, who showed recent clinical instability.
Th e study is the largest trial of adherence therapy to be conducted to date, and the sample size allows adequate statistical power to give a clear answer to the research question.
High levels of treatment fi delity were achieved for both interventions. Th e intervention and control interventions were delivered by trained and clinically experienced therapists, and given over an average of seven sessions each which was realistic clinically (Kemp et al., 1998; O'Donnell et al., 2003) . Th e SF-36 MCS is a well-established measure of direct clinical relevance, which has been used in studies of people with schizophrenia (Meijer et al., 2002) . Research ratings were conducted in a masked fashion, and high rates of followup were achieved.
We shall discuss the interpretation of our fi ndings in terms of the patients referred to and included in the trial, the intervention, the therapists and the timing of assessments.
Over two-thirds of the patients referred to this trial as meeting the inclusion criteria were excluded and not randomised. Almost a third of the patients referred to the study refused to participate, and a further 142 were excluded for other reasons (e.g. they initially agreed to participate and then withdrew, or the research worker was unable to make contact with them). It is possible that this may have biased our sample towards a subsample of more cooperative and adherent people who were unlikely to benefi t from adherence therapy.
Th e sample selection meant that we recruited people who, despite the inclusion criterion of evidence of clinical instability in the previous year, had levels of selfreported treatment adherence which were only moderately impaired (Breen & Th ornhill, 1998; Lacro et al., 2002; Nose et al., 2003b) . It is therefore possible that a ceiling eff ect was operating, in which there was little room for further adherence improvement. Th e subgroup analysis of participants with low treatment adherence, however, suggests there was no benefi cial eff ect of adherence therapy even for the least adherent individuals, compared with health education. In addition, there were low rates of agreement between patient-rated and staff -rated scores of treatment adherence. Th is confi rms previous views that non-invasive measures of treatment adherence are poorly validated, whereas studies using biological assays, such as hair, urine or blood specimens, may be more binnenwerk m kikkert.indd 50 binnenwerk m kikkert.indd 50 9- 1-2010 18:35:16 9-1-2010 18:35:16 valid. However, the latter raise their own problems such as low rates of consent among poorly treatment-adherent patients, and may themselves intervene to change adherence for as long as they take place (Cummings et al., 1984; Matsui et al., 1994; World Health Organization, 2003) .
Th e interventions were off ered in a single course of therapy over 5 months or less, with no booster sessions. Although the number of hours of intervention off ered was as much as most services in these countries could implement routinely, it is possible that this was an insuffi cient dose of treatment to be eff ective, although our data do not suggest even a modest treatment eff ect of adherence therapy compared with health education as delivered. Eff ectiveness might have been reduced by the use of therapists not previously known to the participant. Th is approach is clinically realistic, as it is usual in service studies for structured psychological interventions to be given by therapists not previously known to the patient.
Th e study extends previous work in this fi eld in several respects. Th e results are applicable to patients with schizophrenia in a range of general adult treatment settings, rather than the in-patient samples used in previous studies (Kemp et al., 1998; O'Donnell et al., 2003) . Th e results were consistent across all four study sites in diff erent countries, despite some marked diff erences in patterns of service provision. Our results challenge the conclusions of previous reviews (Nose et al., 2003a; Zygmunt et al., 2002) , which have indicated that such forms of adherence therapy show therapeutic promise. Our study also generates hypotheses for future studies, for example that adherence therapy might be eff ective when delivered by staff who are already members of a multidisciplinary clinical team, or that it might be selectively eff ective only in those patients who are least treatment adherent. Th is study therefore provides evidence of a lack of eff ect for adherence therapy in improving treatment adherence, psychopathology or quality of life of people with schizophrenia. Th e important challenge of how best to assist people with schizophrenia, who are unwilling or unable to adhere to treatment recommendations, therefore remains unresolved.
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